Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 16/20 | 0.62 |
| ▸ | PTPN5 | P54829 | 16/20 | 0.62 |
| ▸ | PTPN2 | P17706 | 15/20 | 0.62 |
| ▸ | HSPD1 | P10809 | 7/20 | 0.62 |
| ▸ | HSPE1 | P61604 | 7/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | XBP1 | P17861 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8280448 | 0.92 | MAPT (0.64) | PTPN1PTPN5PTPN2HSPD1HSPE1 | |
| SCHEMBL712861 | 0.85 | L3MBTL1 (0.47) | PTPN1PTPN5PTPN2HSPD1HSPE1 | |
| SCHEMBL4880510 | 0.81 | PTPN1 (0.72) | PTPN1PTPN5PTPN2HSPD1HSPE1 | |
| SCHEMBL712862 | 0.79 | L3MBTL1 (0.50) | PTPN1PTPN5PTPN2HSPD1HSPE1 | |
| SCHEMBL8278276 | 0.79 | LMNA (0.66) | PTPN1PTPN5PTPN2HSPD1HSPE1 | |
| SCHEMBL31700557 | 0.75 | PTPN2 (1.00) | PTPN1PTPN5PTPN2HSPD1HSPE1 | |
| SCHEMBL8278270 | 0.75 | PFKFB3 (0.51) | MAPT | |
| SCHEMBL8280269 | 0.74 | PFKFB3 (0.53) | — | |
| SCHEMBL8278220 | 0.74 | PGR (0.62) | ALDH1A1MEN1KMT2A | |
| SCHEMBL8279518 | 0.73 | PFKFB3 (0.49) | PTPN1PTPN5PTPN2HSPD1HSPE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-16 | — | — | US | disclosed |
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-16 | — | — | US | disclosed |
| WO-2005090298-A1 | SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | NR1I2, ITGA2, ITGB2 | PTPN1 1619/4885PTPN5 1697/4885PTPN2 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.